Über uns
Über uns
Führungsteam
Unsere Verantwortung
Kollaborationen
Unsere Standorte
Technologie
Technologie
Produktion
Publikationen
Pipeline
Newsroom
News
Events
Downloads
Investor Relations
Überblick
Analysten-Coverage
Hauptversammlung
Finanzberichte
Corporate Governance
E-Mail Alert
Karriere
Werden Sie Teil der RNA people
Ausbildung
Aktuelle Stellenangebote
DE
Most Referenced Publications
Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines
by Sovereign
mRNA mediates passive vaccination against infectious agents, toxins, and tumors
by Sovereign
Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial
by Sovereign
A New RNA-Based Adjuvant Enhances Virus-Specific Vaccine Responses by Locally Triggering TLR- and RLH-Dependent Effects
by Sovereign
A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile
by Sovereign
Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals
by Sovereign
